Revised Financial Statement for the Quarter ended on March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rekvina Laboratories Ltd has submitted a revised version of its financial results for the quarter ended March 2025 to the BSE, replacing the numbers originally filed earlier. A restatement of quarterly financials typically means the company corrected errors, adjusted accounting treatment, or incorporated late information. The specific revised figures (revenue, expenses, profit/loss) are not available in the headline alone and would need to be compared with the earlier submission to identify what changed. Shareholders should review the detailed revised statement and any accompanying notes or auditor remarks to understand the nature and size of the revision.
Revised or restated financial statements can shake investor confidence, especially if the changes are material, and may lead to short-term stock price pressure. Retail investors should compare the revised numbers with the originals and watch for any auditor qualifications or board explanations accompanying the filing.